Sightline Payments Expands Management Team with Appointment of New Chief Financial Officer and Chief Legal Officer

Recent $100 million capital raise helps Sightline also recruit talented Chief Marketing Officer, Chief People Officer and Chief of Staff executives

LAS VEGAS, April 19, 2021 (GLOBE NEWSWIRE) — Sightline Payments, a dynamic Financial Technology company that is enabling the next generation of cashless, mobile and omni-channel payment solutions for the gaming, lottery, sports betting, entertainment and hospitality ecosystems, today announced it has appointed five new executives to its senior leadership team.

John Gronen joins Sightline as Chief Financial Officer of the rapidly growing FinTech provider, while Jennifer Carleton will serve as the Company’s Chief Legal Officer. Through its recent $100 million funding round announced on April 1, Sightline Payments has also appointed Muriel Lotto as Chief Marketing Officer, while Katrina Sevier will serve as its Chief People Officer and Felicia Gassen will be Chief of Staff. The executive appointments strengthen Sightline Payments’ leadership as the company scales to support rapid growth and customer demand.

“We are pleased to welcome John, Jennifer, Muriel, Felicia and Katrina to Sightline Payments. The collective expertise and proven track record that they bring from working with some of the world’s most recognized companies will play an instrumental role in managing the company’s hyper-growth and expansion,” said Joe Pappano, CEO of Sightline Payments. “In the near- and long-term, we plan to invest significant capital in recruiting diverse and expert talent to drive key Sightline priorities around market growth and innovation. Our goal is to have the most talented and diverse team in the gaming and payments industries.”

John Gronen, Chief Financial Officer

John Gronen has been appointed CFO for Sightline where he will oversee all finance operations including banking, treasury, budgeting, and reporting. His experience delivers deep value to the Company having recently served as CFO for payments processor VPay, Inc. and head of operations for VCE, a subsidiary of EMC, Cisco Systems and VMWare. Previously he held senior finance and accounting roles with Technisource, Alltel and Delta Trust and Bank.

John will also play key roles for Sightline in M&A and fundraising in support of the Company’s high-octane organic and inorganic growth strategies.

Jennifer Carleton, Chief Legal Officer

Jennifer Carleton joins Sightline having spent her entire legal career in the gaming sector. She was in-house counsel for an Indian casino and for the last 14 years an adviser to some of the premier public and private gaming and investment companies in the world.

Working in gaming for the past two decades has enabled Jennifer to develop a unique expertise in payments, mobile, internet and sports gaming, as well as an insider’s familiarity with the unique issues that arise when technology and regulation intersect. Jennifer is helping to establish an advanced Indian law and advanced gaming curriculum at the UNLV Boyd School of Law through her teaching at the law school and her work with the Dean’s Advisory Council.

Jennifer also dedicates a substantial amount of time to professional development and corporate philanthropy within her community. She is currently the chair of the Tyler Robinson Foundation, the charitable arm of the Grammy-winning band Imagine Dragons, dedicated to raising funds for pediatric cancer families.

Muriel Lotto, Chief Marketing Officer

Muriel Lotto brings over 25 years in International Marketing to her new role as Sightline Payments’ Chief Marketing Officer. Muriel has worked in France, the United Kingdom, Switzerland and in the United States at leading companies including Nestle, Unilever, Royal & SunAlliance, Bupa and Western Union.

Muriel will lead transformative marketing strategies across audience definition and targeting, customer journeys, messaging, and media mix optimization. In her role, she will drive brand awareness and commercial results through public relations, creative, and advertising partners. 

Katrina Sevier, Chief People Officer

Katrina Sevier brings expertise around the ever-changing organizational landscape of culture and talent. Katrina will be tasked with growing Sightline Payments’ team, which will double in size this year.

Prior to Sightline Payments, Katrina led comprehensive talent strategies delivering growth and implementing change across global organizations in the financial services, technology, media, and advertising industries including Western Union and IPG Mediabrands.

A steadfast believer that the employee and customer experiences are connected, Katrina will build and implement the company’s talent plan to support business growth. 

Felicia Gassen, Chief of Staff

Felicia Gassen has been appointed Chief of Staff to CEO Joe Pappano and the executive leadership team. She is the former Executive Director of Global Gaming Women where she managed the executive board of directors, committees, sponsorship, and global membership. Previously her work included the management of research, grants and education programs in the fields of bioengineering, biotechnology, and bioinformatics. Felicia strongly believes in collaboration, amplifying voices and building connections with people across disciplines. Felicia attended both the University of California, Berkeley and University of Nevada, Las Vegas and holds a BFA in Fine Art and Art History.

For Executive Leadership headshots, please visit: https://sightlinepayments.com/leadership/

About Sightline Payments

Sightline Payments (“Sightline” or the “Company”), is a dynamic Financial Technology (FinTech) company that is enabling the next generation of cashless, mobile and omni-channel payment solutions for the gaming, lottery, sports betting, entertainment and hospitality ecosystems. The Company has more than 1.5 million enrolled Play+ accounts across its current portfolio of more than 70 programs in 39 States, and is poised to build on this presence, commensurate with the expansion visible in the underlying markets it serves. One of the key segments the Company serves is online gaming (both sports betting and iGaming), which is expected to build from $3 billion in total revenue to $22 billion over the next five years. In addition, the Company’s digital payment solutions directly address the wider gaming industry’s opportunity to transform traditional gaming floors into cashless ecosystems, a $90 billion revenue market serving over 100 million customers annually. Sightline is based in Las Vegas, Nevada. Learn more at https://sightlinepayments.com.

Media Contact:

Susan Donahue
Skyya PR for Sightline Payments
[email protected]

 



ChampionX Announces Investment in QLM Technology Ltd

THE WOODLANDS, Texas, April 19, 2021 (GLOBE NEWSWIRE) — ChampionX Corporation (“ChampionX” or the “Company”) (NASDAQ: CHX) announced today the completion of an investment in QLM Technology Ltd, which has developed a revolutionary quantum gas camera with a unique ability to detect, visualize and quantify emissions of methane, helping organizations to achieve net zero through mitigation of emission sources.

“This investment in QLM is consistent with our strategic priority of evaluating opportunities to leverage our core capabilities across the energy market and natural adjacencies to evolve our portfolio for sustained growth through the energy transition,” said Sivasankaran “Soma” Somasundaram, President and Chief Executive Officer of ChampionX.

“We are excited to have ChampionX involved in this funding round as the depth and breadth of their expertise in upstream production wellsite and midstream solutions will be quite valuable to us as we scale up our development and launch our business providing next-generation greenhouse gas monitoring. Our unique quantum Lidar is the right solution for the challenge of how to effectively measure industrial methane emissions and meet the major commitments that many energy companies have made to control their greenhouse gas emissions,” said Dr. Murray Reed, Chief Executive Officer of QLM.


About ChampionX

ChampionX (formerly known as Apergy Corporation) is a global leader in chemistry solutions and highly engineered equipment and technologies that help companies drill for and produce oil and gas safely and efficiently around the world. ChampionX’s products provide efficient functioning throughout the lifecycle of a well with a focus on the production phase of wells.

To learn more about ChampionX, visit our website at www.championX.com.


About QLM Technology Ltd

QLM Technology was founded by its Chief Technical Officer, Dr. Xiao Ai, after postgraduate research into single photon Lidar gas detection at the University of Bristol. He realized that his research, in which a Lidar beam simultaneously probed both the shape and the concentration of plumes of methane, could help achieve Net Zero through mitigation of greenhouse gas emissions. The Quantum Technology Enterprise Centre at the university helped Dr. Ai form QLM Technology Ltd in 2017. Dr. Murray Reed, a photonics industry veteran with thirty years of experience commercializing cutting-edge technology in Silicon Valley, became CEO in June 2019. QLM has been selected as one of 12 Bloomberg New Energy Finance Pioneers for 2021.

To learn more about QLM, visit www.qlmtec.com.

Investor Contact:
Byron Pope – [email protected] – 281-602-0094

Media Contact:
John Breed – [email protected] – 281-403-3751



LGI Homes Opens New Community North of Denver

DENVER, April 19, 2021 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced the opening of Hidden Creek, a new community located north of Denver in Frederick. Incredible community amenities, amazing mountain views and upgraded homes combine for a unique opportunity for affordable homeownership in the Denver area.

Hidden Creek is located in the charming town of Frederick, approximately 27 miles from downtown Denver. Frederick is one of the fastest growing cities in Colorado yet maintains a small-town feel with a rich history and culture. An array of parks and recreation opportunities abound in Frederick including the Carbon Valley Recreation Center, Centennial Park, Frederick Recreation Area and multiple golf courses. The exceptional schools in the St. Vrain Valley School District have received multiple awards and recognition. The town is also home to a variety of events and festivals throughout the year, helping create community amongst residents.

At Hidden Creek, homeowners enjoy unparalleled views of the Rocky Mountains. An extensive walking and biking trail system can be found throughout the community. The neighborhood will also include two family-friendly parks, both offering a playground, swing set, park benches, picnic area, shade ramada and open green space.

LGI Homes offers a lineup of three, four and five-bedroom homes spanning one or two stories. With professional front yard landscaping and two-tone exterior paint schemes, the homes at Hidden Creek offer superb curb appeal. Ranging from 1,465 square feet to 2,684 square feet, each home offers open-concept living areas, private master suites and fully fenced back yards. Select homes have wide front porches, perfect for enjoying the outdoors and taking in the serene landscape. Loaded with the upgrades included in LGI Homes’ CompleteHome™ package, homeowners will find the features and finishes they are seeking without the extra cost. Chef-ready kitchens include sprawling granite countertops, smoke wood cabinets with crown molding, and undermount sinks with Moen® faucets and Power Clean™ spray technology. A full suite of stainless steel Whirpool® kitchen appliances are also included, with a gas range stove, refrigerator with built-in ice maker, dishwasher and microwave. Throughout the kitchen, dining and living areas, you will find luxury vinyl plank flooring and an abundance of natural light from the low-E double-pane windows. New homes at Hidden Creek start in the $430s.

For more information about homes for sale at Hidden Creek, please call 866-831-4955 ext 628 or visit LGIHomes.com/HiddenCreek. To accommodate homebuyers during this time, information centers are open for tours by appointment only and are in compliance with Centers for Disease Control and Prevention and local safety guidelines.

About LGI Homes, Inc.

Headquartered in The Woodlands, Texas, LGI Homes, Inc. engages in the design, construction and sale of homes in Texas, Arizona, Florida, Georgia, New Mexico, Colorado, North Carolina, South Carolina, Washington, Tennessee, Minnesota, Oklahoma, Alabama, California, Oregon, Nevada, West Virginia, Virginia and Pennsylvania. Since 2018, LGI Homes has been ranked as the 10th largest residential builder in the United States based on units closed. The Company has a notable legacy of more than 17 years of homebuilding operations, over which time it has closed more than 45,000 homes. For more information about the Company and its new home developments, please visit the Company’s website at www.lgihomes.com.

MEDIA CONTACT:

Rachel Eaton

(281) 362-8998 ext. 2560

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/63d23565-6292-468a-93a6-7712f04621c7



Inotiv, Inc. Announces Plan to Expand the Company’s Internal Operations

WEST LAFAYETTE, Ind., April 19, 2021 (GLOBE NEWSWIRE) — Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the Company’s plans to expand its St. Louis operations to provide more comprehensive and integrated services, especially in support of the Company’s previously announced planned acquisitions of HistoTox Labs, Inc. and Bolder BioPATH, Inc. The scientific and business teams at the St. Louis location focus on delivering exceptional client experiences with service offerings including pharmacology, toxicology, drug metabolism & pharmacokinetics (“DMPK”), histology, pathology, and cell & molecular biology.

Inotiv plans to exercise the Company’s option to buy the St. Louis facility for approximately $4.7 million and complete an expansion contingent on the Company receiving financing and obtaining related business incentives. The 50,000 square foot facility is comprised of 30,000 square feet of finished laboratory and office space and 20,000 square feet of unfinished shell space. The expansion would finish the shell space, adding office and laboratory capacity to accommodate the Company’s growing client base and diversity of service offerings.

Stewart B. Jacobson, DVM, DACVP, Sr. Vice President, Pathology and St. Louis site leader, commented, “Our expertise enables us to provide thought partnership and laboratory services to pharmaceutical companies as they discover and develop new medicines. We offer a full range of services for clients that seek a consultative laboratory partner. The planned strategic expansion of our DMPK, cell & molecular biology, and investigative pathology laboratory footprint will extend Inotiv’s reach into earlier stages of drug discovery, ultimately increasing engagement of our pharmacology and toxicology operations and histopathology services.”

The expansion will include laboratories for increased DMPK technology and capability, as well as a new cell and molecular biology suite capable of delivering in vitro solutions in pharmacology and toxicology.

“The therapeutic landscape is broadening daily, and versatile laboratory solutions powered by innovation and multidisciplinary teams continue to be a strength of Inotiv’s approach to tailor solutions for clients pursuing small molecule and biotherapeutic discovery,” said Scott Daniels, Ph.D., Sr. Vice President, DMPK.

“Expansion of our operations is part of a strategic investment campaign we initiated at the beginning of 2020 to broaden our laboratory-based solutions and services. The expansion will also offer additional space for continued growth and opportunities from the Bolder BioPATH, Inc. and HistoTox Labs, Inc. acquisitions,” said Robert Leasure, Jr., Company President and Chief Executive Officer. “Investments to date have also included upgrading our technology in mass spectrometry, automation, and flow cytometry technology, as well as recruiting high-level scientific leadership—all of which we believe will directly benefit our clients in their ultimate goal of delivering traditional therapeutics and novel biotherapies to patients.”

About the Company

Inotiv, Inc., is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world’s leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com for more information about the Company.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties and various other market and operating risks, including those detailed in the Company’s filings with the U.S. Securities and Exchange Commission.

Company Contact   Investor Relations
Inotiv, Inc.   The Equity Group Inc.
Beth A. Taylor, Chief Financial Officer   Kalle Ahl, CFA
(765) 497-8381   (212) 836-9614
[email protected]   [email protected] 
     
    Devin Sullivan
    (212) 836-9608
    [email protected] 



Jushi Holdings Inc. to Expand Footprint Through Acquisition of Vertically Integrated Massachusetts Operator

Acquisition to Include Two Retail Dispensaries and a Cultivation and Product Manufacturing Facility

Jushi to Enter Its Seventh State and Expand Retail Footprint to 19 Dispensaries Nationwide

BOCA RATON, Fla., April 19, 2021 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCMKTS: JUSHF), a vertically integrated, multi-state cannabis operator announced that it has reached a definitive binding agreement (the “Agreement”) to acquire Nature’s Remedy of Massachusetts, Inc. and certain of its affiliates (collectively, “Nature’s Remedy”), a vertically-integrated single state operator in Massachusetts, for total consideration of up to US$110 million (the “Acquisition”). Nature’s Remedy currently operates two retail dispensaries, in Millbury, MA and Tyngsborough, MA, and a 50,000 sq. ft. cultivation and production facility in Lakeville, MA with approximately 19,500 sq. ft. of high-quality indoor flower canopy and state-of-the-art extraction and manufacturing capabilities (the “Lakeville Facility”).

“We are excited to announce that we have signed a definitive agreement to acquire Nature’s Remedy, a vertically integrated business operating high-quality, well-managed assets in Massachusetts,” said Jim Cacioppo, Chief Executive Officer, Chairman and Founder of Jushi. “Our entrance into Massachusetts will mark the seventh state where we operate cannabis assets and the third state where we are vertically integrated. This acquisition will enable us to rapidly build scale in an important, maturing adult-use market with a defensible retail position and a solid cultivation footprint with significant opportunities to expand. Upon closing, we look forward to working with the current management team to maximize Nature’s Remedy assets, while introducing our own best-in-class brands and high-quality products to the Massachusetts market [watch video here].” 

Cultivation and Product Manufacturing Facility of Nature’s Remedy

The 50,000 sq. ft. Lakeville Facility is located within a 185,000 sq. ft. industrial complex. Currently, the Lakeville Facility’s flower canopy encompasses approximately 19,500 sq. ft., which Nature’s Remedy expects to expand to approximately 31,000 sq. ft. during the second half of 2021. The Lakeville Facility utilizes CO2 extraction and has a full kitchen for edible production. Current flower production at the Lakeville Facility is approximately 6,800 lbs. / year, which, as part of the expected expansion, Nature’s Remedy could increase to approximately 11,000 lbs. / year based on 31,000 sq. ft. of canopy. In addition to the above-mentioned expansion, Nature’s Remedy is evaluating further expansion opportunities in the existing Lakeville industrial complex and/or on ten acres of land owned by Nature’s Remedy in Grafton, MA. The Lakeville Facility could potentially accommodate an additional 18,000 to 20,000 sq. ft. of flower canopy through the expansion into approximately 26,000 sq. ft. of adjacent space in the existing building. In Grafton, MA, Nature’s Remedy has a Host Community Agreement in place with the city and recently received a provisional cultivation license from the Commonwealth. The ten acres of land in Grafton, MA could potentially accommodate a 35,000 to 40,000 sq. ft. new facility with approximately 18,000 sq. ft. of flower canopy. These expansions are subject to business evaluations and needs, and receipt of applicable regulatory approvals.

Millbury Dispensary

The Millbury dispensary is located in the town of Millbury, MA just south of Worcester, MA. The Millbury dispensary caters primarily to the local population and surrounding underserved areas. The Millbury dispensary provides ample parking for its patrons and is strategically situated along the Worcester-Providence Turnpike, which sees approximately 10,600 cars per day. The Millbury dispensary is located in close proximity to the Shoppes at Blackstone Valley, the largest open-air shopping center in Central Massachusetts, and the Mass Turnpike. Upon closing, Jushi will immediately implement its best-in-class, customer-focused retail approach at the Millbury dispensary, which includes its online reservation ordering platform.

Tyngsborough Dispensary

Tyngsborough is located in northern Middlesex county just south of Nashua, New Hampshire. The Tyngsborough dispensary is strategically located in close proximity to the Pheasant Lane Mall, one of the largest malls in New Hampshire, as well as in close proximity to an exit on Route 3 / Northwest Expressway, which sees 60,000 to 80,000 cars per day. There is ample customer parking with potential for expansion. Upon closing, Jushi will immediately implement its best-in-class, customer-focused retail approach at the Tyngsborough dispensary, which includes its online reservation ordering platform.

Agreement Terms

Under the terms of the Agreement, Jushi has agreed to acquire Nature’s Remedy for an upfront payment of US$100 million (subject to purchase price adjustments as set forth in the Agreement), comprised of US$40.0 million in cash, US$55.0 million in subordinate voting shares of the Company (the “Company Shares”)1 and a US$5.0 million unsecured promissory note.2 The Company has also agreed to issue up to an additional US$10.0 million in Company Shares upon the occurrence or non-occurrence of certain conditions after the closing date (the “Additional Consideration”), bringing the total potential consideration for the Acquisition paid by the Company to US$110 million. The purchase price (inclusive of the full US$10.0 million of Additional Consideration) is expected to represent a multiple of approximately 4.5 to 5.0x Nature’s Remedy’s full year 2021 EBITDA3 and approximately 2.9 to 3.2x Nature’s Remedy’s full year 2022 EBITDA.3

The Acquisition, which is expected to close in the second half of 2021, is subject to certain customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act and approvals from other applicable regulatory authorities. Pursuant to the terms of the Agreement, the Company has the right to terminate the Agreement within 30 days of execution if the Company is not satisfied with its due diligence of Nature’s Remedy for any reason. In addition, the Company has the right to terminate the Agreement if the average of the daily volume weighted average price for a Company Share for the fifteen (15) trading days immediately preceding the closing date (the “Closing Share Price”) would be equal to or less than eighty percent (80%) of the average of the daily volume weighted average price for a Company Share for the fifteen (15) trading days immediately preceding the Agreement’s execution date (the “Execution Share Price”) and Nature’s Remedy has the right to terminate the Agreement if the Closing Share Price would be equal to or less than sixty percent (60%) of the Execution Share Price. There can be no assurance that the Acquisition will be completed.

1
Price per share calculation is equal to the average of the daily volume weighted average price for Company Share (in United States Dollars) on the fifteen (15) trading days immediately preceding the closing date, and which shall not be less than eighty-five percent (85%) of the closing price for a Company Share (in United States Dollars) on the trading day immediately preceding the closing date. 

2
The promissory note provides for cash interest payments to be made quarterly, a five-year maturity and all principal and accrued and unpaid interest due at maturity. 

3
See “Reconciliation of Non-IFRS Financial Measures” at the end of this press release for more information regarding the Company’s use of non-IFRS financial measures.

Watch Jim Cacioppo, CEO, Chairman and Founder of Jushi Holdings Inc. discuss the acquisition of Nature’s Remedy of Massachusetts


Jushi Holdings Inc. to acquire Nature’s Remedy of Massachusetts, Inc. and its affiliates. The $110M deal brings the publicly traded cannabis company a high-quality, well-managed assets in Massachusetts, including a 50K sq. ft. cultivation and production facility in Lakeville. Courtesy of Jushi Holdings. Inc.


Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/4813c94b-8e78-4cde-a8ef-dcb644c1454e

https://www.globenewswire.com/NewsRoom/AttachmentNg/57297739-11a5-406f-8d99-83a20eabda7f

About Jushi Holdings Inc.

We are a vertically integrated cannabis company led by an industry-leading management team. In the United States, Jushi is focused on building a multi-state portfolio of branded cannabis assets through opportunistic acquisitions, distressed workouts, and competitive applications. Jushi strives to maximize shareholder value while delivering high-quality products across all levels of the cannabis ecosystem. For more information, please visit jushico.com or our social media channels, Instagram, Facebook, Twitter, and LinkedIn.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current conditions but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, involve estimates, projections, plans, goals, forecasts, and assumptions that may prove to be inaccurate. As a result, actual results could differ materially from those expressed by such forward-looking statements and such statements should not be relied upon. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or may contain statements that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “will continue,” “will occur” or “will be achieved”.

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has certain expectations and has made certain assumptions. Expectations, assumptions, and risk factors are more fully described in the Company’s Management, Discussion and Analysis for the three months ended September 30, 2020, and other filings with securities and regulatory authorities which are available at www.sedar.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.

Actual results could differ materially from those expressed by such forward-looking statements, and such statements should not be relied upon. Key expectations and assumptions made by Jushi include, but are not limited to, the accuracy of the books and records, and business models of Nature’s Remedy as provided in due diligence; the continued performance of existing operations of Nature’s Remedy; the anticipated expansion of Nature’s Remedy expected by the end of the second quarter of 2021; the expansion and optimization of the Lakeville Facility, adjacent buildings and property in Grafton, MA; and licensing approval. Additional risk factors that may affect actual results are detailed in Jushi’s annual information form and other periodic filings. These documents may be accessed via SEDAR database.


Not for distribution to United States newswire services or for dissemination in the United States.

For further information, please contact:

Investor Relations Contact:

Michael Perlman
Executive Vice President of Investor Relations and Treasury
561-281-0247
[email protected]

Media Contact:

Ellen Mellody
MATTIO Communications
570-209-2947
[email protected]

JUSHI HOLDINGS INC.

RECONCILIATION OF NON-IFRS FINANCIAL MEASURES

EBITDA is a financial measure that is not defined under IFRS, does not have a standardized meaning and therefore may not be comparable to similar measures presented by other issuers.  We define EBITDA as net income (loss), or “earnings”, before interest, income taxes, depreciation, and amortization.

EBITDA is included as a supplemental disclosure because we believe that such measurement provides a better assessment of Nature Remedy’s operations on a continuing basis by eliminating certain material non-cash items and certain other adjustments we believe are not reflective of Nature Remedy’s ongoing operations and performance. EBITDA has limitations as an analytical tool as it excludes from net income as reported interest, tax, depreciation and amortization. Because of these limitations, EBITDA should not be considered as the sole measure of Nature Remedy’s performance or value. The most directly comparable measure to EBITDA calculated in accordance with IFRS is operating income (loss). 



CW Petroleum Corp (CWPE) Launches Social Media Presence on Twitter

Katy, Texas, April 19, 2021 (GLOBE NEWSWIRE) — CW Petroleum Corp (OTCQB: CWPE), a leading provider of Proprietary No-Ethanol Fuels and Biofuels, announce today the launch of the Company’s social media presence on Twitter (@cwpetroleum).

Please find and follow CW Petroleum Corp on Social Media:

The Company has rapidly expanded its sales over the past three years despite COVID-19 and aims for 2021 sales of over $10 million.

As the Company grows, the importance of visibility, transparency, and immediacy in communications grows, emphasizing the value of a growing presence on social and digital media.

For additional information, visit our website at cwpetroleumcorp.com or call 281-817-8099

About CW Petroleum Corp

CW Petroleum Corp supplies and distributes Biodiesel, Biodiesel Blends, Ultra Low Sulfur Diesel Fuel, Gasoline, and a Proprietary EPA Approved Reformulated No Ethanol Gasoline to distributors, convenience stores, marinas, and end-users.

Forward-Looking Statements

Certain statements in this press release may contain “forward-looking statements” regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “endeavors,” “strives,” “may,” or variations of such words and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties, and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in the Company’s most recent annual report on Form 1-K, which may be amended or supplemented by subsequent semiannual reports on Form 1-SA or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to the Company’s filings with the Securities and Exchange Commission.



Media Availability – Canada’s unions respond to Federal Budget 2021

OTTAWA, April 19, 2021 (GLOBE NEWSWIRE) — CLC President Hassan Yussuff and CLC Executive Vice-President Larry Rousseau will be available to comment once the federal budget has been tabled on April 19th. Mr. Yussuff will provide comment in English and Mr. Rousseau will provide comment in French.

Canada’s unions have released their pre-budget submission outlining the top federal budget priorities for workers and their families.

Among the top priorities for Canada’s unions are:

  • fully containing the public health crisis and implementing national pharmacare;
  • investing in the care economy; and
  • getting Canadians back to work and fully-employed in safe, decently-paid, productive and sustainable jobs.
When:    4:15 pm, Monday, April 19, 2021
Who:    Hassan Yussuff, CLC President
    Larry Rousseau, CLC Executive Vice-President

For more information and to set up an interview, please contact:

Chantal St-Denis
CLC Communications
613-355-1962
Email: [email protected]



Autolus Therapeutics announces appointment of Martin Murphy as Non-executive Chairman

LONDON, April 19, 2021 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr Martin Murphy was appointed as non-executive chairman of its Board of Directors, effective April 15, 2021.

Dr Christian Itin has chaired the Autolus Board of Directors since the Company’s inception in 2014 and has also served as chief executive officer since 2016. As the Company’s lead program (AUTO1) continues to progress in multiple clinical trials and the company starts to prepare for commercialization in the event that AUTO1 receives marketing approval, the Company believes that the complexity of the business warrants separation of the roles of chairman and chief executive officer, enabling Dr Itin to fully focus on leading the business. He will remain a member of the Autolus Board.

Dr Murphy has more than 25 years of experience in the life science sector and joined the Autolus Board as a non-executive director at the time of the Company’s inception in 2014. He is currently chief executive officer of Syncona Investment Management Limited, a FTSE-250 listed healthcare investment company and a founding investor in Autolus. He holds, or has previously held, the role of non-executive chairman on the boards of directors of multiple life science companies.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.

About AUTO1 

AUTO1 is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, AUTO1 may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the ability of the programmed T cells to engage in serial killing of target cancer cells. In collaboration with our academic partner, UCL, AUTO1 is currently being evaluated in a Phase 1 clinical trial in adult ALL and B-NHL. The Company has also progressed AUTO1 into a Phase 1/2 clinical trial, referred to as the FELIX study, a potential pivotal trial.

About AUTO1 FELIX study

The Phase 1/2 clinical trial (FELIX) is currently enrolling adult patients with relapsed / refractory ALL. The trial has a limited Phase 1b component prior to proceeding to a single arm Phase 2 clinical trial. The primary endpoint is overall response rate, and the key secondary endpoints include duration of response, MRD negative CR rate and safety. The trial is planned to enroll approximately 100 patients across 30 of the leading academic and non-academic centers in the United States, United Kingdom and Europe.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to, statements regarding the development of the AUTO1 program, including progress, patient enrollment, expectations as to the reporting of data, conduct and timing and potential future clinical activity and regulatory approval, conduct and timing. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks that Autolus’ preclinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the results of early clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many product candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; and the impact of the ongoing COVID-19 pandemic on Autolus’ business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus’ actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Autolus’ Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 4, 2021, as amended, as well as discussions of potential risks, uncertainties, and other important factors in Autolus’ subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Contact:

Julia Wilson
+44 (0) 7818 430877
[email protected]

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
[email protected]



Harbor Custom Development, Inc. Contracts to Develop 99 Lots in Soundview Estates for Lennar Increasing Harbor’s Total Contract Value to $16,830,000

Gig Harbor, Washington , April 19, 2021 (GLOBE NEWSWIRE) — Harbor Custom Development, Inc. (“Harbor,” “Harbor Custom Homes®,” or the “Company”), (NASDAQ:HCDI), an innovative and market leading real estate company involved in all aspects of the land development cycle, today announced that it has entered into a construction contract to develop 99 lots with Lennar Northwest, Inc., a subsidiary of the Lennar Corporation (“Lennar”),  in phase 7 of Soundview Estates located in Bremerton, Washington.

Harbor Custom Homes® previously announced the contract for sale of the 99 undeveloped lots to Lennar on February 18, 2021 and today announced consummation of a construction contract with Lennar to install the infrastructure to develop the property for 99 single family homes on those lots. The two contracts have a combined value of $16,830,000. 

Harbor has also announced the completion of infrastructure improvements on 240 lots at Soundview Estates, of which 215 were purchased by Lennar for single family home construction. With the addition of phase 7, Soundview Estates has grown to a 339-lot subdivision offering spectacular views of the Olympic Mountains, Mt. Rainier, the Seattle Skyline, and Puget Sound. Soundview Estates is less than a ten-minute drive to downtown Bremerton, the Seattle Ferry, and the Kitsap Naval Shipyard.

Soundview Estates can be seen at:  https://vimeo.com/453127877.

“Lennar has been a great partner to work with and has met all our expectations by designing single family homes that meet the needs of residential buyers in Kitsap County.  We look forward to delivering them the final 99 lots in Soundview Estates in 2022 and anticipate they will continue with their current success of constructing quality single family homes that capture the beauty of this unique setting,” stated Sterling Griffin, President and CEO of Harbor Custom Development, Inc.

About Lennar Corporation

Lennar Corporation, founded in 1954, is one of the nation’s leading builders of quality homes for all generations. Lennar builds affordable, move-up, and active adult homes primarily under the Lennar brand name. Lennar’s Financial Services segment provides mortgage financing, title, and closing services primarily for buyers of Lennar’s homes and, through LMF Commercial, originates mortgage loans secured primarily by commercial real estate properties throughout the United States. Lennar’s Multifamily segment is a nationwide developer of high-quality multifamily rental properties. LenX drives Lennar’s technology, innovation, and strategic investments. For more information about Lennar, please visit www.lennar.com.

About Harbor Custom Development, Inc.

Harbor Custom Development, Inc. is a real estate development company involved in all aspects of the land development cycle including land acquisition, entitlements, construction of project infrastructure, home building, marketing, sales, and management of various residential projects in Western Washington’s Puget Sound region; Sacramento, California; and Austin, Texas. Harbor has active or recently sold-out residential communities in Gig Harbor, Bremerton, Silverdale, Bainbridge Island, and Allyn in the state of Washington. In addition, Harbor has acquired land and will begin constructing homes in two new markets beginning the second quarter of 2021. In the Sacramento metro market, Harbor will be constructing homes in completed subdivision in both Rocklin and Auburn, California. In the Austin metro market, Harbor has acquired developed lot inventory in Dripping Springs, Driftwood and Horseshoe Bay Texas. Harbor Custom Development’s business strategy is to acquire and develop land strategically, based on an understanding of population growth patterns, entitlement restrictions, infrastructure development, and geo-economic forces.  Harbor focuses on real estate within target markets with convenient access to metropolitan areas that are generally characterized by diverse economic and employment bases and increasing populations.  For more information on Harbor Custom Development, Inc., please visit www.harborcustomdev.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws.  Words such as “may,” “might,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements.  These forward-looking statements are based upon current estimates and assumptions.  While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release.  These forward-looking statements are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission.  Thus, actual results could be materially different.  The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.



Investor Relations
Hanover International
[email protected]
866-744-0974

NorthShore and Sema4 Launch System-Wide Genomics Program to Improve Primary and Specialty Care with Data-Driven Insights

NorthShore and Sema4 Launch System-Wide Genomics Program to Improve Primary and Specialty Care with Data-Driven Insights

Organizations commit to expanding the impact of genomics and advanced health intelligence among diverse populations to address disparities in personalized health

EVANSTON, Ill. & STAMFORD, Conn.–(BUSINESS WIRE)–NorthShore University HealthSystem (NorthShore) and Sema4, a patient-centered health intelligence company, today announced the availability of a system-wide data-driven genomics program that utilizes predictive analytics to help clinicians and patients prevent, detect, and treat diseases at an early stage, when they are most treatable. As part of the program, NorthShore clinicians and patients will have access to Sema4’s industry-leading, information-rich genomic solutions for hereditary cancer, cardiovascular diseases, pharmacogenomics, and rare diseases.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210419005296/en/

“Unlocking the power of genomics in patient care requires us to make information available in a way that clinicians and patients can easily act upon over time,” said Peter Hulick, MD, director of the Mark R. Neaman Center for Personalized Medicine at NorthShore. “The partnership between NorthShore and Sema4 will allow us to get even better at delivering on the promise of genomic insights to prevent, detect, and manage diseases through one of the largest and most comprehensive personalized medicine programs in the country.”

Advanced Clinical Offerings

By combining clinical information with genomic analysis, Sema4’s technology platform structures and evaluates data sets to draw insights on how genetic variants will impact patients’ chances of developing disease and to determine the most appropriate treatment options, helping their doctors administer more personalized, holistic care plans. NorthShore will have the opportunity to benefit from disease network models developed by Sema4. For example, disease models for cancers will provide more comprehensive views of cancer patients, their tumor progression, and how best to diagnose or treat them.

Amidst the pandemic, as evidence reflects people are delaying preventative care, these more personalized genomic insights are particularly relevant in helping patients and physicians make informed decisions about prioritizing care.

“By narrowing the significant gap between available biomedical data and health and disease information, we are enabling NorthShore clinicians to make real-time use of the latest insights that allow for highly informed decisions at the point-of-care and improved health outcomes,” said Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4. “NorthShore has done what few health systems in the country have – brought the potential of genomics from the research labs to the front lines of care. Through the implementation of Sema4’s innovative health intelligence platform in a clinical-care setting, we are together advancing industry standards.”

Improved Patient and Clinician Experiences

In addition to guiding clinicians, the program makes it easier for NorthShore patients to understand the implications of genomic findings. Novel digital tools and resources will uncover personalized insights that shape the care of multiple conditions throughout the lifetimes of patients. Patients also have an opportunity to consent to share de-identified data to improve research programs focused on expanding the understanding of genomic-guided care.

The strategic alliance between NorthShore and Sema4 will significantly expand on NorthShore’s existing clinical genomics offerings, which were already the largest in routine primary care in the U.S. More than 1,000 physicians and approximately 300,000 NorthShore patients will have access to Sema4’s offerings.

“Precision medicine represents the next major transformation in health care, allowing us to predict and prevent disease, to identify the right treatment at the right time, and to empower patients and clinicians to make better choices about health,” said J.P. Gallagher, President and Chief Executive Officer of NorthShore. “This advanced genomics and health intelligence initiative with Sema4 builds on our long history of pioneering technology and genomic advancements to improve patient care – and aligns with our strong commitment to improving the accessibility of our best-in-class care to address documented disparities in health care services, disease prevalence, and outcomes.”

Addressing Disparities in Care

Due to NorthShore’s intentional focus on increasing access to advanced clinical programs, the program is launching in conjunction with an investment to engage culturally diverse communities. In addition to understanding and addressing barriers to access, NorthShore, via a gift from the Swedish Hospital Foundation, will subsidize genetic testing costs for patients who do not have the financial resources to pay for testing.

Earlier this month, NorthShore began offering the program to patients of Swedish Hospital, a State of Illinois Safety Net Hospital located in a federally designated Medically Underserved Area and a member of the NorthShore family. Through the program, the system expects to gain insights about the views of diverse patient populations towards personalized medicine and barriers to receiving genetic information and testing.

About NorthShore University HealthSystem

Headquartered in Evanston, Illinois, NorthShore is a fully integrated healthcare delivery system that includes six hospitals—Evanston, Glenbrook, Highland Park, Skokie, Swedish and Northwest Community. NorthShore consistently ranks as a Top 15 Major Teaching Hospital in the United States, with an established reputation for exceptional patient care and is a national pioneer in the implementation of advanced health information technology. Together, the NorthShore system provides clinical excellence and community-focused care across Chicagoland. For more information, please visit NorthShore.org, SwedishCovenant.org and NCH.org.

About Sema4

Sema4 is an AI-driven patient-centered genomic and clinical data insight platform company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology. Centrellis™, Sema4’s innovative health intelligence platform, is enabling Sema4 to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all. For more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and YouTube.

NorthShore Media Contact:

Colette Urban

[email protected]

Sema4 Media Contact:

Radley Moss

[email protected]

KEYWORDS: United States North America Illinois Connecticut

INDUSTRY KEYWORDS: Hospitals General Health Health Other Health

MEDIA:

Logo
Logo